Protein Losses in Continuous Ambulatory Peritoneal Dialysis

Rubin, Jack; Nolph, Karl D.; Arfania, Dariush; Prowant, Barbara; Fruto, Leonor; Brown, Phillip P.; Moore, Harold L.

doi:10.1159/000182203

Cited by 51 publications

(17 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Plasma IgG levels were measured in 65 patients, and IgG clearance was calculated as follows: D/P X V /1,440, where D » dialysate IgG concentration, P = plasma IgG concentration, V = dial ysate volume, 1,440 = minutes in 24 h. Plasma proteins were mea sured by the biuret method and albumin by the bromocresol green method. IgG was measured in the 24-hour dialysate and in plasma by commercially available nephelometric methods [8,9] in the hospital laboratory or at commercial laboratories.…”

Section: Methodsmentioning

confidence: 99%

Plasma and Dialysate Immunoglobulin G in Continuous Ambulatory Peritoneal Dialysis Patients: A Multicenter Study

et al. 1990

Self Cite

View full text Add to dashboard Cite

Peritoneal dialysate immunoglobin (Ig)G concentrations were measured in 120 continuous ambulatory peritoneal diaysis (CAPD) patients evaluated at four dialysis centers in different countries to assess the normal range for dialysate IgG and to investigate the relationships of this protein levels with peritoneal episodes, For 65 of these patients, plasma IgG levels were determined, and IgG clearances were calculated. The mean dialysate concentration of IgG was 6.9 ± 4.2 mg/dl, and there was no difference between men and women or between patients who had or had not previously undergone hemodialysis. Dialysate IgG concentrations were significantly related to residual renal creatinine clearance and negatively correlated with dialysate volume, plasma albumin and total protein. There were no significant correlations between IgG levels in the dialysate and age, protein losses in the dialysate, time on CAPD or time from the last peritonitis episode. Plasma and dialysate IgG were unrelated to the incidence of peritonitis, statistical analysis being performed with different methods. These results suggest that IgG levels in the dialysate or plasma are not a major factor in the prevention of CAPD peritonitis.

show abstract

Section: Methodsmentioning

confidence: 99%

Plasma and Dialysate Immunoglobulin G in Continuous Ambulatory Peritoneal Dialysis Patients: A Multicenter Study

et al. 1990

Self Cite

View full text Add to dashboard Cite

show abstract

“…Considerable amounts of protein are removed from the body during peritoneal dialysis (PD), roughly between 5 and 15 g/day during continuous ambulatory PD [1], with albumin representing >90% of the peritoneal protein determined [2]. Several factors can affect the quantity of peritoneal protein loss (PPL), for example, the frequency and duration of the dialysis, the composition of the fluid infused and peritoneal infections [1, 3].…”

Section: Introductionmentioning

confidence: 99%

“…Several factors can affect the quantity of peritoneal protein loss (PPL), for example, the frequency and duration of the dialysis, the composition of the fluid infused and peritoneal infections [1, 3]. In recent studies, PPL has been shown to be associated with the prevalence of peripheral arterial disease (PAD), cardiovascular events and higher mortality in PD patients [4-6].…”

Section: Introductionmentioning

confidence: 99%

Paricalcitol and Peritoneal Protein Loss in Peritoneal Dialysis: A Double-Center Study

et al. 2018

View full text Add to dashboard Cite

Background/Aims: Peritoneal protein loss (PPL) is associated with cardiovascular disease and mortality in peritoneal dialysis (PD). Controversial results have been published about the effect of paricalcitol in PPL among PD patients. This study intends to analyze the relationship between paricalcitol and PPL in PD. Methods: In a retrospective study, prevalent PD patients were divided into 2 groups: “with paricalcitol” and “without paricalcitol”. X²-test, Student’s t test, Pearson correlation coefficient and Logistic Regression analysis were applied. Results: Eighty-two patients were included. PPL was lower among patients medicated with paricalcitol (5.17 ± 1.71 vs. 6.79 ± 2.10 g/24 h, p = 0.0001). In multivariate analysis, paricalcitol and dialysate/plasma ratio of creatinine (D/P creatinine) were independently related to PPL (OR 4.270 [1.437–12.684], p = 0.009 and OR 0.205 [0.064–0.659], p = 0.008, respectively), adjusted for diabetes. Conclusion: Paricalcitol and D/P creatinine were independently related to PPL. Paricalcitol may have an effect on PPL in PD patients

show abstract

“…In addition. CAPD treatment leads to both an increased loss of amino acids and proteins into the dialvsatc [9][10][11][12] and decreased appetite, probably due to peri toneal glucose absorption and abdominal distension by the dialysis solution. Even though most patients maintain normal serum total protein levels and albumin homeosta sis during the initial months on CAPD [13][14][15], long-term CAPD treatment results in decreased total body nitrogen and a reduced protein intake < 1 g/kg body weight/day [13.…”

Section: Introductionmentioning

confidence: 99%

Effect of Amino Acid Based Dialysis Solution on Peritoneal Permeability and Prostanoid Generation in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis

Steinhauer¹,

Lubrich-Birkner²,

Kluthe

et al. 1992

Am J Nephrol

View full text Add to dashboard Cite

The acute effect of amino acid based dialysis solution on peritoneal kinetics of amino acids and plasma proteins in comparison to conventional glucose-based dialysate was studied in 9 patients with end-stage renal failure on continuous ambulatory peritoneal dialysis. Instillation of 2.6% amino acid solution resulted in raised plasma concentrations of all essential amino acids included in the dialysis fluid (p < 0.005). The amino acid solution induced an augmented leakage of plasma proteins into the dialysate at all dwell times investigated (1-8 h). After a dwell time at 8 h, the dialysate total protein increased from 2.62 ± 0.45 g with glucose dialysate to 3.85 ± 0.42 g with amino acid solution (p < 0.05). Corresponding results were obtained for pV microglobulin, albumin, transferrin, IgG, and for the non-essential amino acids alanine, citrulline, and glutamine (p < 0.025) not included in the initial amino acid composition of the dialysis fluid. During the use of amino acid based dialysis fluid, the effluent prostaglandin E2 concentration increased by more than 80% in comparison to glucose dialysate (p < 0.025). The augmented loss of proteins induced by the amino acid solution was positively correlated with increased dialysate prostaglandin E2 (r = 0.8894; p < 0.001). Peritoneal ultrafiltration was not affected by the use of amino acid based dialysate fluid. The present results indicate that amino acid based dialysis fluid enhances the peritoneal permeability for plasma proteins and amino acids, probably mediated by locally generated prostanoids.

show abstract

Protein Losses in Continuous Ambulatory Peritoneal Dialysis

Cited by 51 publications

References 6 publications

Plasma and Dialysate Immunoglobulin G in Continuous Ambulatory Peritoneal Dialysis Patients: A Multicenter Study

Plasma and Dialysate Immunoglobulin G in Continuous Ambulatory Peritoneal Dialysis Patients: A Multicenter Study

Paricalcitol and Peritoneal Protein Loss in Peritoneal Dialysis: A Double-Center Study

Effect of Amino Acid Based Dialysis Solution on Peritoneal Permeability and Prostanoid Generation in Patients Undergoing Continuous Ambulatory Peritoneal Dialysis

Contact Info

Product

Resources

About